Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7FAF

S protein of SARS-CoV-2 in complex bound with P36-5D2 (state1)

7FAF の概要
エントリーDOI10.2210/pdb7faf/pdb
EMDBエントリー31503
分子名称Spike glycoprotein, P36-5D2 heavy chain, P36-5D2 light chain (3 entities in total)
機能のキーワードantibody, sars-cov-2 spike, viral protein, viral protein-immune system complex, viral protein/immune system
由来する生物種Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
詳細
タンパク質・核酸の鎖数9
化学式量合計661947.23
構造登録者
Zhang, L.,Wang, X.,Zhang, S.,Shan, S. (登録日: 2021-07-06, 公開日: 2021-12-22, 最終更新日: 2024-11-06)
主引用文献Shan, S.,Mok, C.K.,Zhang, S.,Lan, J.,Li, J.,Yang, Z.,Wang, R.,Cheng, L.,Fang, M.,Aw, Z.Q.,Yu, J.,Zhang, Q.,Shi, X.,Zhang, T.,Zhang, Z.,Wang, J.,Wang, X.,Chu, J.J.H.,Zhang, L.
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants.
Front Immunol, 12:766821-766821, 2021
Cited by
PubMed Abstract: As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge and spread around the world, antibodies and vaccines to confer broad and potent neutralizing activity are urgently needed. Through the isolation and characterization of monoclonal antibodies (mAbs) from individuals infected with SARS-CoV-2, we identified one antibody, P36-5D2, capable of neutralizing the major SARS-CoV-2 variants of concern. Crystal and electron cryo-microscopy (cryo-EM) structure analyses revealed that P36-5D2 targeted to a conserved epitope on the receptor-binding domain of the spike protein, withstanding the three key mutations-K417N, E484K, and N501Y-found in the variants that are responsible for escape from many potent neutralizing mAbs, including some already approved for emergency use authorization (EUA). A single intraperitoneal (IP) injection of P36-5D2 as a prophylactic treatment completely protected animals from challenge of infectious SARS-CoV-2 Alpha and Beta. Treated animals manifested normal body weight and were devoid of infection-associated death up to 14 days. A substantial decrease of the infectious virus in the lungs and brain, as well as reduced lung pathology, was found in these animals compared to the controls. Thus, P36-5D2 represents a new and desirable human antibody against the current and emerging SARS-CoV-2 variants.
PubMed: 34966387
DOI: 10.3389/fimmu.2021.766821
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.69 Å)
構造検証レポート
Validation report summary of 7faf
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon